Sign up USA
Proactive Investors - Run By Investors For Investors

Proactive Investors One2One Investor Forum - London

Midatech Pharma Plc | Amryt Pharmaceuticals | Ergomed Plc | Avacta Group Plc

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception. Details on the presenting companies can be found below.

 

This event is suitable for the following:

Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.

 

The event is not suitable for people pursuing commercial opportunities.


Register


Amryt Pharmaceuticals

RSS Portfolio

amryt-pharma.jpg


Amryt Pharma is a specialty pharmaceutical company focused on the developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.

EPIC: AMYT
Market: AIM
52-week High/Low: 31.20p / 13.44p
Market Cap: 40.11M


View full company profile

Avacta Group Plc

RSS Portfolio

avacta.png


Avacta’s principal focus is on its proprietary Affimer® platform, a novel engineered alternative to antibodies that has wide application in diagnostics, therapeutics and research.

Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer proteins, which can be quickly generated to bind with high specificity and affinity to a wide range of targets, have been designed to address these negative performance issues. 

Avacta has a pre-clinical drug development programme with a primary focus on immuno-oncology as well as partnered development programmes. Avacta is also commercialising non-therapeutic Affimer reagents through licensing to developers of research tools and diagnostics.

EPIC: AVCT
Market: AIM
52-week High/Low: 116.00p / 61.50p
Market Cap: 43.08M


View full company profile

Ergomed Plc

RSS Portfolio

Ergomed-logo.png


Founded in 1997, Ergomed plc is a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs. It operates globally in over 40 countries.

Ergomed plc has two complementary businesses:
(1) The Services Business – a well-established, clinical research business providing services to the pharmaceutical and biotechnology industry; and
(2) The Co-Development Business – a growing portfolio of partnerships with pharmaceutical and biotech companies, providing its drug development services in exchange for a carried interest in any revenues attributable to the drug asset, including outlicensing milestones as well as sales of the product

EPIC: ERGO
Market: AIM
52-week High/Low: 216.88p / 117.00p
Market Cap: 79.59M


View full company profile

Midatech Pharma Plc

RSS Portfolio

Midatech_pharma.png


Midatech is an international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas.

 

EPIC: MTPH
Market: AIM
52-week High/Low: 189.90p / 100.51p
Market Cap: 40.92M


View full company profile
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use